文献速递眼底病与葡萄膜炎

比较阿柏西普、贝伐珠单抗与雷珠单抗治疗2年糖尿病视网膜病变变化:一项随机临床试验的二次分析

Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

该预计划二次分析纳入650例中心受累型糖尿病黄斑水肿患者,随机接受阿柏西普2.0 mg、贝伐珠单抗1.25 mg或雷珠单抗0.3 mg治疗。1年时非增殖性糖尿病视网膜病变(NPDR)眼中阿柏西普和雷珠单抗的视网膜病变改善率高于贝伐珠单抗,2年时三组无差异;基线增殖性糖尿病视网膜病变(PDR)眼中阿柏西普1年改善率高于贝伐珠单抗,且差异似维持至2年。三种抗VEGF药物均与较低的视网膜病变恶化率相关。

要点

  • 1年时NPDR眼阿柏西普和雷珠单抗的DR改善率高于贝伐珠单抗,2年时三组无差异。
  • 基线PDR眼中阿柏西普1年改善率高于贝伐珠单抗,差异似维持至2年。
  • 三种抗VEGF药物治疗的2年DR恶化累积率均较低,组间无统计学显著差异。

核心结论

  • 接受抗VEGF治疗DME的NPDR眼在1年和2年时可能出现DR严重程度改善。
  • 1年时贝伐珠单抗的改善少于阿柏西普或雷珠单抗。
  • 在基线PDR的较小亚组中,阿柏西普在1年和2年时与更多改善相关。
  • 所有三种抗VEGF治疗均与低DR恶化率相关。

研究设计与样本

  • 比较有效性试验的预计划二次分析,纳入650例中心受累型DME参与者接受阿柏西普、贝伐珠单抗或雷珠单抗治疗。
  • 参与者于2012年至2013年随机分组,试验于2015年9月23日结束。
  • 随机分配至阿柏西普2.0 mg、贝伐珠单抗1.25 mg或雷珠单抗0.3 mg,按再治疗方案最多每4周一次至2年。

主要发现

  • 1年时423只NPDR眼中,阿柏西普组141眼中44眼(31.2%)、贝伐珠单抗组131眼中29眼(22.1%)、雷珠单抗组151眼中57眼(37.7%)DR严重程度改善(校正差值:阿柏西普vs贝伐珠单抗11.7%,95%CI 2.9%至20.6%,P=.004;雷珠单抗vs贝伐珠单抗8.9%,95%CI 1.7%至16.1%,P=.01;阿柏西普vs雷珠单抗2.9%,95%CI -5.7%至11.4%,P=.51)。
  • 2年时阿柏西普组33眼(24.8%)、贝伐珠单抗组25眼(22.1%)、雷珠单抗组40眼(31.0%)DR改善,未发现治疗组间差异。
  • 基线93只PDR眼中,1年改善率阿柏西普75.9%、贝伐珠单抗31.4%、雷珠单抗55.2%(校正差值:阿柏西普vs贝伐珠单抗50.4%,95%CI 26.8%至74.0%,P<.001;雷珠单抗vs贝伐珠单抗20.4%,95%CI -3.1%至44.0%,P=.09;阿柏西普vs雷珠单抗30.0%,95%CI 4.4%至55.6%,P=.02),这些率和治疗组差异似维持至2年。
  • 1年时改善的NPDR眼中66眼(59.5%)、PDR眼中28眼(70.0%)在2年时维持改善,尽管第二年注射次数减少。
  • 2年DR恶化累积率在NPDR眼为7.1%至10.2%、PDR眼为17.2%至26.4%,未注意到统计学显著的治疗差异。

临床怎么用

  • 这些数据提供了选择抗VEGF药物治疗DME时可能考虑的额外结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents. OBJECTIVE: To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME. DESIGN, SETTING, AND PARTICIPANTS: Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab. Retinopathy improvement and worsening were determined during 2 years of treatment. Participants were randomized in 2012 through 2013, and the trial concluded on September 23, 2015. INTERVENTIONS: Random assignment to aflibercept, 2.0 mg; bevacizumab, 1.25 mg; ranibizumab, 0.3 mg, up to every 4 weeks through 2 years following a retreatment protocol. MAIN OUTCOMES AND MEASURES: Percentages with retinopathy improvement at 1 and 2 years and cumulative probabilities for retinopathy worsening through 2-year without adjustment for multiple outcomes. RESULTS: A total of 650 participants (495 [76.2%] nonproliferative DR [NPDR], 155 proliferative DR [PDR]) were analyzed; 302 (46.5%) were women and mean (SD) age was 61 (10) years; 425 (65.4%) were white. At 1 year, among 423 NPDR eyes, 44 of 141 (31.2%) treated with aflibercept, 29 of 131 (22.1%) with bevacizumab, and 57 of 151 (37.7%) with ranibizumab had improvement of DR severity (adjusted difference: 11.7%; 95% CI, 2.9% to 20.6%; P = .004 for aflibercept vs bevacizumab; 8.9%; 95% CI, 1.7% to 16.1%; P = .01 for ranibizumab vs bevacizumab; and 2.9%; 95% CI, -5.7% to 11.4%; P = .51 for aflibercept vs ranibizumab). At 2 years, 33 eyes (24.8%) in the aflibercept group, 25 eyes (22.1%) in the bevacizumab group, and 40 eyes (31.0%) in the ranibizumab group had DR improvement; no treatment group differences were identified. For 93 eyes with PDR at baseline, 1-year improvement rates were 75.9% for aflibercept, 31.4% for bevacizumab, and 55.2% for ranibizumab (adjusted difference: 50.4%; 95% CI, 26.8% to 74.0%; P < .001 for aflibercept vs bevacizumab; 20.4%; 95% CI, -3.1% to 44.0%; P = .09 for ranibizumab vs bevacizumab; and 30.0%; 95% CI, 4.4% to 55.6%; P = .02 for aflibercept vs ranibizumab). These rates and treatment group differences appeared to be maintained at 2 years. Despite the reduced numbers of injections in the second year, 66 (59.5%) of NPDR and 28 (70.0%) of PDR eyes that manifested improvement at 1 year maintained improvement at 2 years. Two-year cumulative rates for retinopathy worsening ranged from 7.1% to 10.2% and 17.2% to 26.4% among anti-VEGF groups for NPDR and PDR eyes, respectively. No statistically significant treatment differences were noted. CONCLUSIONS AND RELEVANCE: At 1 and 2 years, eyes with NPDR receiving anti-VEGF treatment for DME may experience improvement in DR severity. Less improvement was demonstrated with bevacizumab at 1 year than with aflibercept or ranibizumab. Aflibercept was associated with more improvement at 1 and 2 years in the smaller subgroup of participants with PDR at baseline. All 3 anti-VEGF treatments were associated with low rates of DR worsening. These data provide additional outcomes that might be considered when choosing an anti-VEGF agent to treat DME.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bressler SB, Liu D, Glassman AR, et al. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017. PMID: 28448655. doi:10.1001/jamaophthalmol.2017.0821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。